Predicting Postoperative Lung Cancer Recurrence and Survival Using Cox Proportional Hazards Regression and Machine Learning
Source check: Source checked. Not independent scientific confirmation.
Finding: Publisher full text read in Chrome, Methods and Results: retrospective cohort 309/512 NSCLC lung-resection patients; CT radiomic/body-composition features with Cox regression and ML (logistic/SVM among approaches), five-fold validation, AUC about .75–.77. Specific recurrence/survival association with no external cohort. Publisher also links a later comment/reply (Cancers 2025, 17(4), 697; 17(5), 727) critiquing limitations in variable interpretation; the reply acknowledges the issue and plans alternative approaches, which qualifies causal/mechanistic interpretation but does not negate the reported predictive association. This record is limited to the study result and does not establish independent replication or real-world benefit.
Technology: Logistic regression and SVM
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Publisher full text read in Chrome, Methods and Results: retrospective cohort 309/512 NSCLC lung-resection patients; CT radiomic/body-composition features with Cox regression and ML (logistic/SVM among approaches), five-fold validation, AUC about .75–.77. Specific recurrence/survival association with no external cohort. Publisher also links a later comment/reply (Cancers 2025, 17(4), 697; 17(5), 727) critiquing limitations in variable interpretation; the reply acknowledges the issue and plans alternative approaches, which qualifies causal/mechanistic interpretation but does not negate the reported predictive association.
- Test and result
- Publisher full text read in Chrome, Methods and Results: retrospective cohort 309/512 NSCLC lung-resection patients; CT radiomic/body-composition features with Cox regression and ML (logistic/SVM among approaches), five-fold validation, AUC about .75–.77. Specific recurrence/survival association with no external cohort. Publisher also links a later comment/reply (Cancers 2025, 17(4), 697; 17(5), 727) critiquing limitations in variable interpretation; the reply acknowledges the issue and plans alternative approaches, which qualifies causal/mechanistic interpretation but does not negate the reported predictive association.
- Limitation / still unknown
- No prospective clinical benefit or broader external validity is established by the documented study.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.mdpi.com/2072-6694/17/1/33
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.